![Yves Lévy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Yves Lévy is the founder of Linkinvax SA, serving as Chief Scientific Officer since 2020.
Mr. Lévy is currently the Director at Global HIV Vaccine Enterprise.
Formerly, Mr. Lévy was the Chairman & Chief Executive Officer at Institut National de la Santé & de la Recherche Médicale.
Actieve functies van Yves Lévy
| Bedrijven | Functie | Begin |
|---|---|---|
Global HIV Vaccine Enterprise
 Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Develops preventive HIV vaccines | Directeur/Bestuurslid | - |
Linkinvax SA
 Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Oprichter | 01-01-2020 |
Eerdere bekende functies van Yves Lévy
| Bedrijven | Functie | Einde |
|---|---|---|
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
16
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Research institute | Commercial Services |
Global HIV Vaccine Enterprise
Global HIV Vaccine Enterprise Miscellaneous Commercial ServicesCommercial Services Develops preventive HIV vaccines | Commercial Services |
Linkinvax SA
Linkinvax SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company to develops disrupt vaccine using a unique dendritic cell-targeting vaccine platform | Commercial Services |
